All Publications | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 2 results.

- Journal article
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan, Brian G Sandborn, William J D'Haens, Geert Panés, Julián Kaser, Arthur Ferrante, Marc Louis, Edouard Franchimont, Denis Dewit, Olivier[UCL] Seidler, Ursula Kim, Kyung-Jo Neurath, Markus F Schreiber, Stefan Scholl, Paul Pamulapati, Chandrasena Lalovic, Bojan Visvanathan, Sudha Padula, Steven J Herichova, Ivona Soaita, Adina Hall, David B Böcher, Wulf O (2017) The Lancet — Vol. 389, no.10080, p. 1699-1709 (2017)
- Journal article
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan, Brian G Panés, Julián Ferrante, Marc Kaser, Arthur D'Haens, Geert R Sandborn, William J Louis, Edouard Neurath, Markus F Franchimont, Denis Dewit, Olivier[UCL] Seidler, Ursula Kim, Kyung-Jo Selinger, Christian Padula, Steven J Herichova, Ivona Robinson, Anne M Wallace, Kori Zhao, Jun Minocha, Mukul Othman, Ahmed A Soaita, Adina Visvanathan, Sudha Hall, David B Böcher, Wulf O (2018) The lancet. Gastroenterology & hepatology — Vol. 3, no. 10, p. 671-680 (2018)